Skip to content
  • Sunday, 26 July 2026
  • 2:58 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • OrsoBio’s LXR Inverse Agonist Shows Promise for Hard-to-Treat Triglyceride Disorders, Paving New Path Beyond GLP-1 Dominance
Laboratory Automation & Robotics

OrsoBio’s LXR Inverse Agonist Shows Promise for Hard-to-Treat Triglyceride Disorders, Paving New Path Beyond GLP-1 Dominance

Lana Keisha Apr 14, 2026 0

OrsoBio, a specialized biotechnology firm dedicated to pioneering therapies for obesity and its associated metabolic conditions, is strategically charting a…

Read More
Laboratory Automation & Robotics

OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders

Lana Keisha Apr 3, 2026 0

OrsoBio, a specialized biotechnology company strategically focused on addressing obesity and its myriad related metabolic dysfunctions, is charting a course…

Read More
Laboratory Automation & Robotics

OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders

Lana Keisha Mar 26, 2026 0

OrsoBio, a specialized biotechnology firm dedicated to pioneering treatments for obesity and its associated metabolic disorders, is strategically charting a…

Read More
Laboratory Automation & Robotics

OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders and pioneering a new frontier in obesity therapeutics

Lana Keisha Mar 19, 2026 0

OrsoBio, a dynamic biotech enterprise dedicated to advancing novel therapies for obesity and a spectrum of obesity-related metabolic disorders, is…

Read More
New Research Uncovers a Novel Mechanism Linking Light and Plant Growth Regulation Through Enhanced Tissue AdhesionAbbVie Secures FDA Approval for Ultra-Rare Blood Cancer Therapy, While AstraZeneca Faces Delay for Breast Cancer DrugScience News: A Century of Empowering Public Understanding of Science, Medicine, and TechnologyA Hidden Housekeeping Gene Holds the Key to Enhanced Fruit Quality Without Compromising Plant Growth
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ